Maxim Group analyst Naureen Quibria maintained a Buy rating on Galmed Pharmaceuticals (GLMD) yesterday and set a price target of $10.00. The company’s shares closed last Friday at $4.57.
According to TipRanks.com, Quibria is a 3-star analyst with an average return of 12.0% and a 45.5% success rate. Quibria covers the Healthcare sector, focusing on stocks such as Inovio Pharmaceuticals, Achieve Life Sciences, and Onconova Therapeutics.
Currently, the analyst consensus on Galmed Pharmaceuticals is a Strong Buy with an average price target of $19.86, representing a 334.6% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $29.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.38 and a one-year low of $3.02. Currently, Galmed Pharmaceuticals has an average volume of 93.23K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. The Aramchol is a synthetic conjugate of cholic acid, or a type of bile acid, and arachidic acid, or a type of saturated fatty acid, both of which, in their non-synthetic forms, are naturally occurring. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
Read More on GLMD:
